Frailty Index May Predict Outcomes in Older Patients

Share this content:
Frailty Index May Predict Outcomes in Older Patients
Frailty Index May Predict Outcomes in Older Patients

A deficit-accumulation frailty index constructed from a comprehensive geriatric assessment may predict outcomes in older patients with cancer, according to a study published in the journal Cancer.1

Because frailty has been suggested as a domain for clinicians to consider when treating older patients with cancer, researchers sought to evaluate a frailty index from a mostly self-administered comprehensive geriatric assessment.

For the study, 500 patients age 65 years and older underwent the geriatric assessment prior to the receipt of chemotherapy. Investigators constructed the 51-item frailty index, and then examined cutoff values for patients in the robust/nonfrail (cutoff value, 0.0 to less than 0.2), prefrail (cutoff value, 0.2 to less than 0.35), and frail (cutoff value, 0.35 or greater) groups.

Of those evaluated, 50% were considered were nonfrail, 39% were prefrail, and 11% were frail. Researchers found that older age (80 years or older), lower education, living alone, and higher stage of disease were associated with prefrail/frail status.

Results showed that prefrail/frail patients were more likely to experience grade 3 or worse toxicities but not to require dose interruption or reduction. They also had a higher likelihood of drug discontinuation and hospitalization.

"The frailty status so determined is associated both with outcomes likely because of chemotherapy toxicity and with those likely because of age-related physiologic and functional deficits and thus can be useful in the overall assessment of the patient," the authors concluded.


1. Cohen HJ, Smith D, Sun CL, et al. Frailty as determined by a comprehensive geriatric assessment-derived deficit-accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016 Aug 16. doi: 10.1002/cncr.30269. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs